VivoSeq
Psychiatry

Irritability Associated With Autism Spectrum Disorder

4

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Irritability Associated With Autism Spectrum Disorder is an early-stage landscape with 4 programs across 2 companies. The most active players are Bristol-Myers Squibb, Eli Lilly. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Not yet recruiting2 · 50%

Clinical Trials

Trial Activity

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone in the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients 5 to 17 Years of Age
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 3·NCT06706674·160 enrolled
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone in the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients 5 to 17 Years of Age
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 3·NCT06690398·160 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
Not yet recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07285798·176 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
Not yet recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07284745·176 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)